Sterling Accuris acquires Gujarat Pathology Lab to expand Ahmedabad network

Sterling Accuris Diagnostics has announced the acquisition of Gujarat & Maha Gujarat Pathology Laboratories, a pathology service provider based in Ahmedabad. The transaction is expected to increase Sterling Accuris’ operational footprint in the city and expand its diagnostic service offerings. Ste

Apr 16, 2025 - 13:00

Sterling Accuris acquires Gujarat Pathology Lab to expand Ahmedabad network

Sterling Accuris Diagnostics said it will acquire Gujarat & Maha Gujarat Pathology Laboratories, a pathology service provider based in Ahmedabad. The transaction is expected to increase Sterling Accuris’ operational footprint in the city and expand its diagnostic service offerings.

Sterling Accuris, established in 2015, is a chain of NABL-accredited pathology laboratories operating across Gujarat, Rajasthan, and Madhya Pradesh. The company currently manages over 75 laboratories and 300 collection centres across India.

This is Sterling Accuris’ fourth acquisition in the past two years. According to Sterling Accuris, the acquisition will support its plans to expand its service network in Ahmedabad and strengthen its presence in the B2C segment of the diagnostics market.

“The diagnostic market in India is growing rapidly. According to recent research, the pathology segment is projected to grow at a CAGR of 14% between 2025 and 2030. Gujarat Pathology Laboratory is our fourth acquisition in the last two years. Acquiring Gujarat Pathology Laboratory is a strategic move that aligns with our growth vision, and I am confident this will elevate Sterling Accuris to new heights," said Ankush Gupta, CEO of Sterling Accuris.

Gujarat Pathology Laboratory, founded in 1998, operates eight laboratories and more than 20 collection centres in Ahmedabad. The laboratory offers a range of diagnostic services, including hematology, biochemistry, immunology, and molecular biology, and has served approximately 2 million patients to date.

“Gujarat Pathology Laboratory has been serving Ahmedabad for the past 27 years, with a strong presence and reputation in the market. Our acquisition of Gujarat Pathology Laboratory will enable us to serve a larger patient base in Ahmedabad by leveraging their strengths in the B2C segment. This collaboration will not only strengthen our service network but also enhance the reach and quality of diagnostic services we offer across Ahmedabad Gujarat," Rajiv Sharma, Managing Director of Sterling Accuris.

Sterling Accuris has implemented various digital platforms to support its operations, including a multilingual chatbot, a mobile application, and centralized customer care systems.

Morgan Stanley Private Equity Asia is an investor in Sterling Accuris Wellness Private Limited.

India’s diagnostics sector has seen a significant uptick in mergers and acquisitions since the start of 2024, as larger players pursue consolidation to strengthen regional presence, expand service portfolios, and gain access to high-growth markets.

Metropolis Healthcare has been one of the most active acquirers during this period. In December 2024, it acquired Delhi-based Core Diagnostics for Rs 247 crore, bolstering its capabilities in high-end cancer diagnostics and expanding its footprint across Northern and Eastern India. This was followed by the March 2025 acquisition of Scientific Pathology, a well-known Agra-based diagnostic chain, for a consideration between Rs 55 crore and Rs 83 crore.

In a similar strategic expansion, Manipal HealthMap acquired a 100% stake in iGenetic Diagnostics, a Mumbai-based lab chain specializing in molecular diagnostics and critical care testing. The acquisition allows Manipal HealthMap to deepen its portfolio of advanced diagnostic services.

Meanwhile, Dr. Lal PathLabs has signaled its intention to expand aggressively in southern India. The company is actively scouting small- and mid-sized labs in Tamil Nadu, Karnataka, and Andhra Pradesh. With a surplus cash reserve of nearly Rs 1,000 crore earmarked for acquisitions, Dr. Lal PathLabs is expected to be a key player in the next wave of sector consolidation.

These developments underscore a broader trend of strategic consolidation in India’s diagnostics landscape. Companies are acquiring established regional labs to gain scale, expand geographically, and tap into the growing demand for preventive and specialty diagnostics services. With private equity interest and digital integration also on the rise, the sector is likely to see continued deal activity through 2025

Edited by Jyoti Narayan